Optimizing Subtyping-Based Therapy in Triple-Negative Breast Cancer

1. The median progression-free survival was improved with the pooled subtyping-based therapy group compared to the control group (11.3 months vs 5.8 months with an HR 0.44). 2. Grade 3-4 adverse events occurred in 57% of the subtyping-based group and 31% in the control group with the most common being neutropenia, anemia, and increased alanine […]

The post Optimizing Subtyping-Based Therapy in Triple-Negative Breast Cancer first appeared on 2 Minute Medicine.